康宁corning耗材 155379 LAB-TekTMⅡ,腔室盖玻片,1.5硼酸硅玻璃,通过CE认证,已灭菌,孔数,2 LSP Nunc 96 1CS
日度归档:2024年10月4日
Bis-sulfone-PEG4-DBCO
上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Bis-sulfone-PEG4-DBCO
Bis-sulfone-PEG4-DBCO 是一种 PROTAC linker,属于 PEG 类。可用于合成 PROTAC 分子。
Bis-sulfone-PEG4-DBCO Chemical Structure
CAS No. : 1854034-70-0
规格 | 是否有货 | ||
---|---|---|---|
5 mg | 询价 | ||
10 mg | 询价 | ||
25 mg | 询价 | ||
50 mg | 询价 |
* Please select Quantity before adding items.
生物活性 |
Bis-sulfone-PEG4-DBCO is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1]. |
|
---|---|---|
IC50 & Target |
|
|
体外研究 (In Vitro) |
PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1]. Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only. |
|
分子量 |
1006.19 |
|
Formula |
C54H59N3O12S2 |
|
CAS 号 |
1854034-70-0 |
|
运输条件 |
Room temperature in continental US; may vary elsewhere. |
|
储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis. |
|
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
康宁corning耗材 155361 LAB-TekTMⅡ,腔室盖玻片,1.0硼酸硅玻璃,通过CE认证,已灭菌,孔数,1 LSP Nunc
康宁corning耗材 155361 LAB-TekTMⅡ,腔室盖玻片,1.0硼酸硅玻璃,通过CE认证,已灭菌,孔数,1 LSP Nunc 96 1CS
康宁corning耗材 155360 LAB-TekTMⅡ,腔室盖玻片,1.5硼酸硅玻璃,通过CE认证,已灭菌,孔数,1 LSP Nunc
康宁corning耗材 155360 LAB-TekTMⅡ,腔室盖玻片,1.5硼酸硅玻璃,通过CE认证,已灭菌,孔数,1 LSP Nunc 96 1CS
康宁corning耗材 154941 LAB-TekTMⅡ-CC2TM,腔室玻片,已灭菌,通过CE认证,孔数,8 LSP Nunc
康宁corning耗材 154941 LAB-TekTMⅡ-CC2TM,腔室玻片,已灭菌,通过CE认证,孔数,8 LSP Nunc 96 1CS
Onvansertib(Synonyms: NMS-1286937; NMS-P937)
上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Onvansertib (Synonyms: NMS-1286937; NMS-P937) 纯度: 99.32%
nMS-1286937 是一种有效、高选择性、可口服的 PLK1 抑制剂,IC50 值为 2 nM。
Onvansertib Chemical Structure
CAS No. : 1034616-18-6
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
Free Sample (0.1-0.5 mg) | Apply now | ||
10 mM * 1 mL in DMSO | ¥762 | In-stock | |
5 mg | ¥650 | In-stock | |
10 mg | ¥1000 | In-stock | |
50 mg | ¥2600 | In-stock | |
100 mg | ¥4900 | In-stock | |
200 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
Onvansertib 相关产品
•相关化合物库:
- Drug Repurposing Compound Library Plus
- Clinical Compound Library Plus
- Bioactive Compound Library Plus
- Apoptosis Compound Library
- Cell Cycle/DNA Damage Compound Library
- Kinase Inhibitor Library
- Anti-Cancer Compound Library
- Clinical Compound Library
- Anti-Aging Compound Library
- Drug Repurposing Compound Library
- Orally Active Compound Library
- Anti-Blood Cancer Compound Library
- Targeted Diversity Library
生物活性 |
NMS-1286937 is a potent, selective and orally available PLK1 inhibitor, with an IC50 of 2 nM. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1] |
|
||||||||||||||||
体外研究 (In Vitro) |
NMS-1286937 is a potent, selective and orally available PLK1 inhibitor, with IC50 of 2 nM. NMS-1286937 also shows inhibitory activities against FLT3, MELK, and CK2, with IC50s of 510, 744, and 826 nM, respectively[1]. NMS-P937 possesses a pure ATP competitive mechanism with a reversible dissociation and no time dependency. NMS-P937 (10 μM) is selective with a marginal activity of 48% and 40% inhibition on PLK2 and PLK3, respectively. NMS-P937 shows antiproliferative activity against a panel of 137 cell lines, with IC50 values of below 100 nM for 60 of 137 cell lines and higher than 1 μM for only 9 of 137 cell lines[2]. NMS-P937 shows cytotoxic activity against AmL-NS8 cells with IC50 of 36 nM[3]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
体内研究 (In Vivo) |
NMS-1286937 (45 mg/kg, i.v.) shows a good tumor growth inhibition with acceptable and reversible body weight loss in CD1 nu/nu mice xenografted with human HCT116 colon adenocarcinoma cells. NMS-1286937 (60 mg/kg, p.o.) also inhibits the growth of tumor on HCT116 xenograft model[1]. NMS-P937 (45 mg/kg, i.v.or 60 mg/kg, p.o) inhibits tumor growth to a comparable degree (TGI, 83% and 79% intravenously and orally, respectively) in HCT116-bearing mice. The combination of NMS-P937 (120 mg/kg given for 4 cycles of 2 consecutive days with 10-day rest) and cytarabine (75 mg/kg for 4 cycles of 5 consecutive days with 7-day rest) in the disseminated leukemia model AmL-PS is well tolerated and clearly showed increased mice survival[2]. NMS-P937 (60 mg/kg bid os per day over 2 days with a 5 day rest) shows good efficacy compared to standard therapies, with a significant increase in median survival time (MST) in the established disease setting[3]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
Clinical Trial |
|
||||||||||||||||
分子量 |
532.52 |
||||||||||||||||
Formula |
C24H27F3N8O3 |
||||||||||||||||
CAS 号 |
1034616-18-6 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 21 mg/mL (39.44 mM; Need ultrasonic and warming) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
Kinase Assay [1] |
The inhibitory activity of putative kinase inhibitors and the potency of selected compounds are determined using a trans-phosphorylation assay. Specific peptide or protein substrates are trans-phosphorylated by their specific serine-threonine or tyrosine kinase, in the presence of ATP traced with 33P-γ-ATP, at optimized buffer and cofactors conditions. At the end of the phosphorylation reaction, more than 98% unlabeled ATP and radioactive ATP is captured by adding an excess of the ion exchange dowex resin; the resin then settles down to the bottom of the reaction plate by gravity. Supernatant, containing the phosphorylated substrate, is subsequently withdrawn and transferred into a counting plate, followed by evaluation by b-counting. Inhibitory potency evaluation for all the tested kinases is performed at 25°C using a 60 min end-point assay where the concentrations of ATP and substrates are kept equal to 2 × αKm and saturated (>5 × αKm), respectively. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
---|---|
Cell Assay [2] |
Cells are seeded into 96- or 384-well plates at densities ranging from 10,000 to 30,000/cm2 for adherent and 100,000/mL for nonadherent cells in appropriate medium supplemented with 10% fetal calf serum. After 24 hours, cells are treated in duplicate with serial dilutions of NMS-P937, and 72 hours later, the viable cell number is assessed by the CellTiter-Glo Assay. IC50 values are calculated with a sigmoidal fitting algorithm. Experiments are carried out independently at least twice. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
Animal Administration [2] |
For carcinoma xenograft studies, 5- to 6-week-old female Hsd, athymic nu/nu mice (average weight, 20-22 g), are used. HCT116, HT29, Colo205 colorectal, and A2780 ovarian human carcinoma cell lines are inoculated subcutaneously. Mice bearing a palpable tumor (100-200 mm3) are treated with vehicle or NMS-P937 following doses and schedules starting from the day after randomization. Tumor dimensions are measured regularly with Vernier calipers, and tumor growth inhibition (TGI) is calculated. Toxicity is evaluated on the basis of body weight reduction. For leukemia studies, 5- to 6-week-old female severe combined immunodeficient mice (SCID; average weight, 20-22 g) are used. The AmL cell line HL-60 (5×106 cells) is injected subcutaneously and treatments initiated when tumor size reaches 200 to 250 mm3. Tumor dimensions and TGI are assessed. For disseminated models, 5×106 AmL primary cells (AmL-PS) are injected intravenously and treatments start after 2 days. Mice are monitored daily for clinical signs of disease, and the median survival time is determined for each group. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
康宁corning耗材 154917 LAB-TekTMⅡ-CC2TM,腔室玻片,已灭菌,通过CE认证,孔数,4 LSP Nunc
康宁corning耗材 154917 LAB-TekTMⅡ-CC2TM,腔室玻片,已灭菌,通过CE认证,孔数,4 LSP Nunc 96 1CS
NVP-ADW742(Synonyms: ADW742; GSK 552602A; ADW)
上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
NVP-ADW742 (Synonyms: ADW742; GSK 552602A; ADW) 纯度: 99.30%
NVP-ADW742 (ADW742) 是一种具有口服活性,选择性的 IGF-1R 酪氨酸激酶抑制剂,IC50 为 0.17 μM。NVP-ADW742 抑制胰岛素受体 (InsR),IC50 为 2.8 μM。NVP-ADW742 在肿瘤细胞中诱导多效性抗增殖/促凋亡 (apoptosis)。
NVP-ADW742 Chemical Structure
CAS No. : 475488-23-4
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO | ¥1197 | In-stock | |
2 mg | ¥800 | In-stock | |
5 mg | ¥1200 | In-stock | |
10 mg | ¥2000 | In-stock | |
50 mg | ¥6700 | In-stock | |
100 mg | ¥12000 | In-stock | |
200 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
NVP-ADW742 相关产品
•相关化合物库:
- Bioactive Compound Library Plus
- Apoptosis Compound Library
- Kinase Inhibitor Library
- Protein Tyrosine Kinase Compound Library
- Anti-Cancer Compound Library
- Anti-Aging Compound Library
- Differentiation Inducing Compound Library
- Endocrinology Compound Library
- Orally Active Compound Library
- Anti-Pancreatic Cancer Compound Library
- Angiogenesis Related Compound Library
生物活性 |
NVP-ADW742 (ADW742) is an orally active, selective IGF-1R tyrosine kinase inhibitor with an IC50 of 0.17 μM. NVP-ADW742 inhibits insulin receptor (InsR) with an IC50 of 2.8 μM. NVP-ADW742 induces pleiotropic antiproliferative/proapoptotic biologic sequelae in tumor cells[1][2]. |
IC50 & Target |
IC50: 0.17 μM (IGF-1R) and 2.8 μM (InsR)[1] |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
NVP-ADW742 (ADW742; 0.1-10 µM; 72 hours) dose-dependently inhibits serum-induced cell growth in all cell lines[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay[1]
Western Blot Analysis[1]
|
||||||||||||||||
体内研究 (In Vivo) |
NVP-ADW742 (ADW742; 10 mg/kg for IP or 50 mg/kg for orally; twice daily for 19 days) significantly suppresses tumor growth and prolongs the survival of mice[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||||||
分子量 |
453.58 |
||||||||||||||||
Formula |
C28H31N5O |
||||||||||||||||
CAS 号 |
475488-23-4 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 19.23 mg/mL (42.40 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
康宁corning耗材 154852 LAB-TekTMⅡ-CC2TM,腔室玻片,已灭菌,通过CE认证,孔数,2 LSP Nunc
康宁corning耗材 154852 LAB-TekTMⅡ-CC2TM,腔室玻片,已灭菌,通过CE认证,孔数,2 LSP Nunc 96 1CS
康宁corning耗材 154739 LAB-TekTMⅡ-CC2TM,腔室玻片,已灭菌,通过CE认证,孔数,1 LSP Nunc
康宁corning耗材 154739 LAB-TekTMⅡ-CC2TM,腔室玻片,已灭菌,通过CE认证,孔数,1 LSP Nunc 96 1CS
康宁corning耗材 154534 Lab-TekTMⅡ腔室玻片,已灭菌,通过CE认证,孔数,8 LSP Nunc
康宁corning耗材 154534 Lab-TekTMⅡ腔室玻片,已灭菌,通过CE认证,孔数,8 LSP Nunc 96 1CS
康宁corning耗材 154526 Lab-TekTMⅡ腔室玻片,已灭菌,通过CE认证,孔数,4 LSP Nunc
康宁corning耗材 154526 Lab-TekTMⅡ腔室玻片,已灭菌,通过CE认证,孔数,4 LSP Nunc 96 1CS
Biotin alkyne
上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Biotin alkyne 纯度: 98.03%
Biotin alkyne 是一种 PROTAC linker,属于 PEG 类。可用于合成 PROTAC 分子。
Biotin alkyne Chemical Structure
CAS No. : 773888-45-2
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
10 mg | ¥850 | In-stock | |
25 mg | ¥1500 | In-stock | |
50 mg | ¥2500 | In-stock | |
100 mg | 询价 | ||
200 mg | 询价 |
* Please select Quantity before adding items.
生物活性 |
Biotin alkyne is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1]. |
|
---|---|---|
IC50 & Target |
|
|
体外研究 (In Vitro) |
PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1]. Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only. |
|
分子量 |
281.37 |
|
Formula |
C13H19N3O2S |
|
CAS 号 |
773888-45-2 |
|
运输条件 |
Room temperature in continental US; may vary elsewhere. |
|
储存方式 |
-20°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
|
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
康宁corning耗材 154461 Lab-TekTMⅡ腔室玻片,已灭菌,通过CE认证,孔数,2 LSP Nunc
康宁corning耗材 154461 Lab-TekTMⅡ腔室玻片,已灭菌,通过CE认证,孔数,2 LSP Nunc 96 1CS
康宁corning耗材 154453 Lab-TekTMⅡ腔室玻片,已灭菌,通过CE认证,孔数,1 LSP Nunc
康宁corning耗材 154453 Lab-TekTMⅡ腔室玻片,已灭菌,通过CE认证,孔数,1 LSP Nunc 96 1CS
康宁corning耗材 153732 带透气/密封瓶盖的NunclonTM△培养瓶,聚苯乙烯,已灭菌,培养面积,80cm2 LSP Nunc
康宁corning耗材 153732 带透气/密封瓶盖的NunclonTM△培养瓶,聚苯乙烯,已灭菌,培养面积,80cm2 LSP Nunc 50 1CS
TOFA(Synonyms: RMI14514; MDL14514)
上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
TOFA (Synonyms: RMI14514; MDL14514) 纯度: 99.57%
TOFA (RMI14514;MDL14514)是乙酰辅酶A羧化酶-α (ACCA )的变构抑制剂。
TOFA Chemical Structure
CAS No. : 54857-86-2
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO | ¥550 | In-stock | |
5 mg | ¥500 | In-stock | |
10 mg | ¥700 | In-stock | |
50 mg | ¥2550 | In-stock | |
100 mg | ¥4350 | In-stock | |
200 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
TOFA 相关产品
•相关化合物库:
- Bioactive Compound Library Plus
- Metabolism/Protease Compound Library
- Anti-Cancer Compound Library
- Anti-Lung Cancer Compound Library
- Anti-Cancer Metabolism Compound Library
- Anti-Obesity Compound Library
- Lipid Metabolism Compound Library
- Targeted Diversity Library
生物活性 |
TOFA (RMI14514;MDL14514) is an allosteric inhibitor of acetyl-CoA carboxylase-α (ACCA ). |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
TOFA (5-tetradecyloxy-2-furoic acid) is cytotoxic to lung cancer cells NCI-H460 and colon carcinoma cells HCT-8 and HCT-15, with an IC50 at approximately 5.0, 5.0, and 4.5 μg/mL, respectively. TOFA at 1.0–20.0 μg/mL effectively blocks fatty acid synthesis and induces cell death in a dose-dependent manner[1]. TOFA is found to be cytotoxic to COC1 and COC1/DDP cells with IC50 values of ~26.1 and 11.6 µg/mL, respectively. TOFA inhibits the proliferation of the cancer cells examined in a time and dose dependent manner, arrests the cells in the G0/G1 cell cycle phase and induces apoptosis[2]. Acetyl-CoA-carboxylase-α (ACCA) is a key enzyme in the regulation of fatty acids synthesis. Inhibition of ACCA by TOFA decreases fatty acid synthesis and induces caspase activation and cell death in most PCa cell lines[3]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
体内研究 (In Vivo) |
TOFA inhibits COC1/DDP cell growth in ovarian tumor mouse xenografts. The tumor growth rate is signifi¬cantly inhibited by TOFA compared with the DMSO treated control mice (1649±356.3 vs. 5128±390.4 mm3. No toxicity is observed in the heart, liver, spleen, lung, kidney and intestinal tissues. By inhibiting ACC, TOFA may be a promising small molecule agent for ovarian cancer therapy[2]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
分子量 |
324.45 |
||||||||||||||||
Formula |
C19H32O4 |
||||||||||||||||
CAS 号 |
54857-86-2 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 11.36 mg/mL (35.01 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
|
||||||||||||||||
参考文献 |
|
Cell Assay [1] |
NCI-H460, human lung cancer cells, and HCT-8 and HCT-15 cells (5,000/well) are seeded in 96-well plates overnight and then exposed to TOFA at indicated concentrations (0, 1, 5, 10, 20, 50 µg/mL) for 72 hours. Viable cells are detected using MTT assay[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
---|---|
Animal Administration [2] |
Mice: Mice are treated with 50 μL DMSO (control group) or treated with TOFA (50 mg/kg). The drugs are injected intraperitoneally daily for two weeks. Tumor volumes are recorded every two days by measuring dimensions (length and width) with Vernier calipers. The mice are sacrificed four weeks after the final treatment. Tumor weights are measured by a scale[2]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
康宁corning耗材 152640 Nunc多孔细胞培养板,聚苯乙烯,带盖,已灭菌,孔数,48,建议工作容量,0.5ml/孔,每包/箱数,5/85 LSP Nunc
康宁corning耗材 152640 Nunc多孔细胞培养板,聚苯乙烯,带盖,已灭菌,孔数,48,建议工作容量,0.5ml/孔,每包/箱数,5/85 LSP Nunc 85 1CS
康宁corning耗材 152041 384孔底透微孔板,聚苯乙烯/聚合物基座,外部尺寸128*86mm,表面,Collagen 1,颜色,黑色,带盖 LSP Nunc 5
康宁corning耗材 152041 384孔底透微孔板,聚苯乙烯/聚合物基座,外部尺寸128*86mm,表面,Collagen 1,颜色,黑色,带盖 LSP Nunc 5 20 1CS
Fostamatinib Disodium(Synonyms: 福他替尼二钠盐; R788(Disodium))
上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Fostamatinib Disodium (Synonyms: 福他替尼二钠盐; R788(Disodium)) 纯度: 99.88%
Fostamatinib Disodium (R788 Disodium) 是 R406 的口服前药。R406 是一种有效的,具有口服活性的,ATP 竞争性的 Syk/FLT3 抑制剂,Ki 为 30 nM,IC50 为 41 nM。R406 还抑制 Lyn (IC50=63 nM) 和 Lck (IC50=37 nM).
Fostamatinib Disodium Chemical Structure
CAS No. : 1025687-58-4
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO | ¥1374 | In-stock | |
5 mg | ¥1000 | In-stock | |
10 mg | ¥1600 | In-stock | |
50 mg | ¥4500 | In-stock | |
100 mg | ¥7500 | In-stock | |
200 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
Fostamatinib Disodium 相关产品
•相关化合物库:
- Drug Repurposing Compound Library Plus
- FDA-Approved Drug Library Plus
- FDA-Approved Drug Library Mini
- Bioactive Compound Library Plus
- Immunology/Inflammation Compound Library
- Kinase Inhibitor Library
- Protein Tyrosine Kinase Compound Library
- FDA-Approved Drug Library
- Anti-Cancer Compound Library
- Drug Repurposing Compound Library
- Diabetes Related Compound Library
- Anti-COVID-19 Compound Library
- Orally Active Compound Library
- FDA Approved & Pharmacopeial Drug Library
- Anti-Blood Cancer Compound Library
- Rare Diseases Drug Library
生物活性 |
Fostamatinib Disodium (R788 Disodium) is the oral prodrug of the active compound R406[1]. R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM[2]. R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM)[3]. |
IC50 & Target |
Syk, FLT3[2] |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体内研究 (In Vivo) |
Fostamatinib (R788) is highly bioavailable, and rapidly absorbed in Louvain rats. R406 following a single oral dose of R788 10 mg/kg or 20 mg/kg: AUC0-16 hrs= 10618 ng*h/mL and 30650 ng*h/mL respectively; Cmax=2600 ng/mL and 6500 ng/mL respectively (observed at 1 hour); t1/2=4.2 hours. The prodrug was not detected in plasma suggesting R788 is completely converted to R406[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
Clinical Trial |
|
||||||||||||||||
分子量 |
624.42 |
||||||||||||||||
Formula |
C23H24FN6Na2O9P |
||||||||||||||||
CAS 号 |
1025687-58-4 |
||||||||||||||||
中文名称 |
福他替尼二钠盐 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 50 mg/mL (80.07 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务